Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) (SPERA)

This study is ongoing, but not recruiting participants.
Information provided by GPC Biotech

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Prostate Cancer
2		Additional conditions recognized in this trial
			Prostatic Neoplasms
3		More general conditions related to this trial
			Genital Diseases, Male
			Genital Neoplasms, Male
			Neoplasms
			Neoplasms by Site
			Prostatic Diseases
			Urogenital Neoplasms
4		Interventions listed in this trial
			Oral Satraplatin
5		Additional drug interventions recognized in this trial
			Satraplatin
6		More general drug interventions related to this trial
			Antineoplastic Agents
			Pharmacologic Actions
			Therapeutic Uses
7		Sponsors listed in this trial
			GPC Biotech